David Thomas, FRACP, PhD, director and division head, Genomic Cancer Medicine, Cancer Division, Garvan Institute of Medical Research, discusses the genomic features of sarcoma and how they factor into the treatment landscape of this disease.
Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas
June 13th 2024Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.
Read More
High CR Rate in BCG-Unresponsive NMIBC With Cretostimogene Grenadenorepvec/Pembro
June 5th 2024A high complete response rate was achieved in patients with BCG–unresponsive NMIBC using the combination of cretostimogene grenadenorepvec and pembrolizumab, according to final phase 2 CORE-001 trial results.
Read More